The application period for the DKMS John Hansen Research Grant 2024 began on August 1, 2023. With this grant, the foundation DKMS Stiftung Leben Spenden supports up to four outstanding research projects in the field of stem cell transplantation or cell therapy each year. A stem cell transplant saves the lives of many blood cancer patients. However, relapses and severe complications continue to pose major challenges. The grant is intended to promote excellent science in this field. The application deadline is November 30, 2023.

Immun Checkpoint-Inhibitoren (ICI) sind hochwirksame Medikamente in der modernen Krebstherapie. Ihr Einsatz hat auch bei Melanompatient:innen die Überlebenschancen verbessert. Aber nicht alle Erkrankten profitieren gleichermaßen. Ein Team von Forschenden der Medizinischen Fakultät der Universität Duisburg-Essen und Deutschem Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Essen/Düsseldorf, hat nun einen Faktor gefunden, der das Ansprechen auf die ICI-Therapie maßgeblich beeinflusst: das Zytokin Interleukin-17, kurz IL-17. Die Ergebnisse wurden kürzlich in „Nature Cancer“ veröffentlicht.

Researchers from the Leibniz Institute on Aging in Jena and the Brandenburg University of Technology Cottbus-Senftenberg have discovered a novel treatment approach for soft tissue tumors, which are frequently occurring in children and are often malignant. Through the targeted transformation of the tumor cells into muscle cells, they succeeded in stopping the growth of the cells and thereby the growth of the tumor. This opens completely new therapeutic options in cancer treatment.

Glioblastomas are among the most aggressive kinds of brain tumors. Even immunotherapy treatments that have proved effective against other cancers seem to be powerless against them. Researchers at the University of Basel and University Hospital Basel have now described how to improve the immune system’s chances against this type of tumor.

Groundbreaking method offers a fast and cost-effective way to observe abnormal metabolic processes live in the magnetic resonance imaging (MRI) scanner / Production of biological contrast agents / Publication in Angewandte Chemie International Edition

A research team at Helmholtz Munich revealed a specific mechanism that is able to promote cell death in cancer cells by pharmacological targeting of a ferroptosis surveillance system.

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis.

An interdisciplinary team of researchers at the Otto-von-Guericke University in Magdeburg has gained new insights into how inflammatory mediators of pathogen defense can remotely drive cancer cells into death – an important contribution to improving cancer immunotherapies.

The spliceosome is the molecular machine in our cells that puts the blueprints for proteins into a readable form. Researchers at the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen (Germany) and the Institute for Cancer Research (ICR) in London (UK) have now uncovered the crucial step that switches on the spliceosome. As they have shown, this macromolecular machine is activated by two molecular motors. The findings from the study could provide new approaches to improve potential cancer drugs that target the splicing process.

Das Spleißosom ist die molekulare Maschine in unseren Zellen, die die Bauanleitungen für Proteine in eine lesbare Form bringt. Forschende am Göttinger Max-Planck-Institut (MPI) für Multidisziplinäre Naturwissenschaften und am Institute for Cancer Research (ICR) in London (Großbritannien) haben jetzt den entscheidenden Schritt aufgedeckt, der das Spleißosom anschaltet. Wie sie zeigen konnten, wird es durch zwei molekulare Motoren aktiviert. Die Erkenntnisse aus der Studie könnten neue Ansätze liefern, um potenzielle Krebsmedikamente zu verbessern, die auf den Spleiß-Prozess abzielen.

More heat-related deaths, new and increasing infectious diseases, increased exposure to allergens, a rise in antibiotic resistance, more lung diseases as a result of increasing air pollution, more skin cancer due to increased UV radiation – these are some of the negative consequences of climate change for public health. A new report, coordinated by the Robert Koch Institute (RKI), provides an overview of the health impacts of climate change and ways to counteract them. The publication was coordinated through the project KlimGesundAkt, which is funded by the Federal Ministry of Health.

The cancer gene MYC drives unrestrained growth of most human cancers. It has been called the “Mount Everest” of cancer research because of the difficulty of designing medications that can disable it, and the expectation that an effective MYC drug could help so many cancer patients. Research groups from the The Wertheim UF Scripps Institute in Florida, the Max Planck Institute of Molecular Physiology in Dortmund and the University of Münster have joined forces and climbed that peak by developing Nature-inspired compounds chopping up MYC’s RNA. This innovative RNA degrader approach could also open new routes to summit other similarly hard-to-treat diseases.

To prevent our body’s cells from overflowing with garbage and to keep them healthy, the waste inside them is constantly being disposed of. This cleaning process is called autophagy. Scientists have now, for the first time, rebuilt the complex nanomachine in the laboratory that starts this process – and it works quite differently from other cellular machines. The researchers’ new insights could help open up new approaches for the treatment of cancer, immune disorders, and neurodegenerative diseases in the future, and possibly even delay aging.

Anlässlich des „European Cancer Nursing Day“ am 18. Mai 2023 präsentiert die Universitätsmedizin Halle „GRAN-ONCO“ – die erste Forschungsagenda für die onkologische Pflege in Deutschland.

An international team of researchers from the University of Georgia, USA, and the Max Planck Institute for Chemical Ecology in Jena, presents a promising strategy for elucidating metabolic pathways for plant compounds of medicinal importance. The research team studied the biosynthesis of two alkaloids from the plant Catharanthus roseus that are used in human medicine as anti-cancer agents. By using single-cell analyses, the scientists were able to discover new genes important for biosynthesis and show that the intermediates of the metabolic pathway accumulate in specific cell types.

Should patients over the age of 70 with head and neck cancer receive aggressive combined radiotherapy and chemotherapy? This is a controversial issue among patients, their families and health professionals. A large-scale international study involving Leipzig University Hospital proves the effectiveness of this combined treatment in older patients. The findings have recently been published in the journal JAMA Network Open.

How do the nerve cells in our brain communicate with each other? What processes take place when T cells render cancer cells harmless? Details of the mechanisms at the cellular level remain hidden from view. Now, special reporter proteins developed by a research team led by the Technical University of Munich (TUM) may help unveil these mechanisms.

«Physics against cancer» ist ein Buch über die Entstehung der Protonentherapie am Paul Scherrer Institut PSI.

Ein Konsortium der Onkologischen Spitzenzentren (Comprehensive Cancer Center) in Dresden, Frankfurt-Marburg und Leipzig/Jena entwickelt eine neuartige Gentherapie zur Behandlung eines besonders bösartigen hirneigenen Tumors (Glioblastom). Ziel ist es, gleichzeitig ein Tumor-unterdrückendes Gen (p53) in die Krebszellen einzuschleusen und Mechanismen zu unterbinden, welche die Genfunktion blockieren können. Hierfür entwickeln die Wissenschaftlerinnen und Wissenschaftler unter anderem ein neues Nanopartikel-Transportsystem.

Almost every fourth person who dies of cancer has a hollow organ tumour, for example in the bile duct or in the oesophagus. Such a tumour cannot usually be removed surgically. It is only possible to open the hollow organ for a short time using a stent, i.e. a tube-shaped prosthesis. However, the tumour grows back and penetrates the hollow organ through the stent. Ioana Slabu from the Institute of Applied Medical Technology and Benedict Bauer from the Institut für Textiltechnik of RWTH Aachen University have now developed a novel technology for the therapy of hollow organ tumours, which was awarded second place in the RWTH Innovation Award.

Damage in the human genome can be repaired. But this works better in germ cells, sperm and eggs, than in normal body cells. Responsible for this is the DREAM protein complex, which prevents the activation of all available repair mechanisms. A research team at the University of Cologne has now shown that normal body cells can also be repaired better once this complex has been deactivated. In the long run, the scientists hope to develop better therapies to prevent cancer and aging-associated diseases. They describe their results in ‘Nature Structural & Molecular Biology’

For in vivo studies of internal processes in an organism, body pigmentation is a considerable limitation. To circumvent this, various transparent fish models have already been generated, and are used in cancer research, among other things. In research on aging, however, these fish are rarely being used due to their relatively long lifespan of up to five years. Researchers at the Leibniz Institute on Aging – Fritz Lipmann Institute (FLI) in Jena have now succeeded, with the help of the CRISPR/Cas9 technology, in generating a transparent killifish (N. furzeri) called “klara”, which, with a maximum lifespan of only one year, is ideal for in vivo studies of age-related processes.

Resistance to HER2-targeted therapies can be a problem when treating patients with HER2-positive (HER2+) breast cancer. Therefore, the identification of new therapies for this patient group is important. Researchers at the Leibniz Research Centre for Working Environments and Human Factors in Dortmund (IfADo) have already shown that the enzyme EDI3 is associated with changes in the metabolism of cancer cells. Their most recent results reveal that inhibiting EDI3 may be a new therapeutic target in patients with therapy-resistant ER-HER2+ breast cancer.

The accumulation of the metabolite fumarate in the mitochondrion, the powerhouse of a cell, can cause inflammation associated with diseases such as cancer and autoimmune diseases / Publication in Nature

RIANA Therapeutics, a promising pharmaceutical start-up recently spun out of the University of Veterinary Medicine Vienna (Vetmeduni), aims to develop novel therapeutics for cancer patients based in part on scientific findings from Vetmeduni’s Moriggl research group (Moriggl Lab). The technological basis is a proprietary platform technology for the discovery of drugs that target cancer-causing protein-protein interactions (PPIs).